New technologies delivered to your inbox Subscribe
2015-311 – Mayo Clinic has discovered that HEATR1 is a novel Akt regulator and a predictor for chemoradioresistance.
2015-312 – Mayo Clinic has discovered that the Parkin protein is a mitotic regulator. Cancer cells with deficiency or mutations in Parkin have an increase in mitotic regulator expression leading to tumorigenesis and an increase in sensitivity of Pk1 and Aurora kinase inhibitors. This newly identified mechanism has revealed that Parkin mutations may be used as a biomarker for measuring the sensitivity of... Read More
2015-164 – Mayo Clinic has discovered that WSB1 can be used as a diagnostic marker for tumor metastasis and a therapeutic target.
2017-036 – Mayo Clinic has discovered that inhibition of stearoyl-CoA desaturase 1, SCD1 - a key enzyme fatty acid metabolism, in combination with PD1/PD-L1 inhibition enhances T cell based cancer immunotherapy.
2017-176 – Mayo Clinic has discovered that novel SCD1 inhibitors can be used to treat liver cancer.
2016-386 – Mayo Clinic has discovered the UFM1 signaling pathway as a biomarker/therapeutic target in cancer. UFM1 is an Ub-like molecule needed for ATM activation and DNA damage response. Inhibiting the pathway could sensitize cancer cells to radiation and chemotherapy.
2016-055 – Mayo Clinic has discovered the functional roles for DUB3, an ubiquitin specific protease, and CDK4/6 inhibitors, in their ability to regulate cancer metastasis. CDK4/6 inhibitors blocked triple-negative breast cancer metastasis.
2015-196 – Mayo Clinic has discovered that BET inhibitors hinder the homologous recombination process in DNA repair and that BET inhibitors sensitize tumors to PARP inhibitor treatment.
Therapeutic Modulation of the MoCo Biosynthesis Pathway to Protect Neurons and Axons from Inflammation-Induced Injury
2014-299 – Mayo Clinic has developed an innovative therapeutic strategy to use molybdenum cofactor (MoCo) to treat neurological inflammatory disease.
2012-209 – Mayo Clinic researchers have developed methods and materials for treating cancer through the use of antigen combinations. For example, Vesicular Stomatitis Virus (VSV) vectors designed to express a GNAQ antigen, a TYRP1 anti-gen, and an N-RAS antigen can be used to reduce the number of cancer cells (e.g., uveal melanoma cells) within a mammal. In some cases, VSV vectors designed to express... Read More
2015-151 – Several novel naturally processed and HLA presented influenza A/H5N1-derived peptides from a class I HLA-A0201 molecules have been identified. A mass spectrometry approach was used to identify five influenza peptides from a B-cell line (homozygous for HLA-A0201) after infection with influenza A/H5N1 virus. The immunologic relevance and specificity of these identified influenza-derived... Read More
2014-330 – An adult hypomorphic model of Propionic acidemia (PA) in Pcca− mice using a transgene bearing an A138T mutant of the human PCCA protein. Pcca−/−(A138T) mice have 2% of wild-type PCC activity, survive to adulthood, and have elevations in propionylcarnitine, methylcitrate, glycine, alanine, lysine, ammonia, and markers associated with cardiomyopathy similar to those in patients with PA. Data... Read More
2014-229 – Computer modeling followed by synthesis of novel compounds and testing for stearoyl CoA desaturase 1 (SCD1) specific growth inhibition of cancer cells has led to the identification of four novel lead SCD1 inhibitors.
2012-062 – Broad patent claims have issued claiming methods for treating renal cell carcinoma by using SCD1 inhibitors and are available for licensing.
2010-040 – Mouse overexpressing PAPP-A in arterial smooth muscle for the study of atherosclerotic lesion development. Genotype/Phenotype: A modified SM22alpha promoter with a deleted repressor element drives smooth muscle overexpression. Upon crossbreeding with ApoE knockout mice, PAPP-A transgenic mice develop larger atherosclerotic lesions than ApoE knockout mice. Utility: Model for examining the... Read More
2013-312 – A series of novel prodrugs of K channel openers demonstrated significant intraocular pressure (IOP) lowering in normal mice and in a mouse model of glaucoma. The IOP lowering response obtained from using a K channel openers prodrug combined with other glaucoma drugs on the market seems to be somewhat synergistic
2012-253 – Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are devastating neurodegenerative diseases. FTLD results from the degeneration of the frontal and temporal lobes of the brain, and encompasses a group of disorders distinguished by abnormalities in behavior, language and personalityl. ALS is characterized by the degeneration of motor neurons, resulting in muscle... Read More
2012-098 – Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.
2012-050 – We have shown that a combination of these vesicular stomatis viruses (VSV) that encode N-Ras, cytochrome c (ctyc), or Tyrosinase-related protein 1(TYRP1), can be used to treat melanoma. Previously, we had shown that the use of a cDNA library in packaged in VSV can treat cancer. Here we show that a combination of three particular VSVs with the cDNA of N-Ras, cyt-c and Tryp 1 given... Read More
A Novel Method to Identify Antigens Which Act Co-Operatively To Treat Established Tumors Using Viral-Expressed cDNA Libraries
2012-049 – We describe a novel technology to define new repertoires of tumor antigen(s) which work alone or in combination to generate anti tumor immune responses. Definition of arrays of antigens which co-operate in vivo to cure established tumors will inform future strategies for novel clinical vaccines through the use of vesicular stomatis virus with cDNA libraries constructed with selected, relevant... Read More
2011-245 – Immune responses directed toward many cancers are characterized by targeted cell-killing activities mediated by cytotoxic T cells (a.k.a. Thl responses). However, certain tumors such as bladder cancer, instead appear to elicit immune responses that are traditionally linked with allergies (a.k.a. Th2 responses). These immune responses also include the tissue recruitment of rare white blood... Read More
2011-184 – Methods and Materials for Assessing Responsiveness PARP Inhibitors and Platinating Agents Methods and materials have been developed for assessing responsiveness to PARP inhibitors and platinating agents by using levels of non-homogous end-joining (NHEI) pathway members to determine if cancer cells that are homologous recombination (hr) - deficient are likely to be susceptible or resistant... Read More
2011-065 – Three decades after the eradication of smallpox, the threat of bioterrorism and outbreaks of emerging diseases such as monkeypox have renewed interest in the development of safe and effective next-generation poxvirus vaccines and biodefense research. Current smallpox vaccines contain live virus and are contraindicated for a large percentage of the population. Safer, yet still effective... Read More
2011-042 – DNA Aptamers Promoting Remyelination in Neurodegenerative Disease Single-stranded DNA aptamers 40 nucleotides in length were selected for binding to mouse myelin and were evaluated for their ability to promote remyelination. This approach was based upon previous reports indicating that IgM antibodies are capable of promoting remyelination in animal models of multiple sclerosis. After... Read More
2011-027 – RU486 for Decreasing Suppressive Monocytes in Cancer and Sepsis Suppressive monocytes have been found in a number of different conditions including sepsis, cancer, and trauma victims. Presence of large numbers of these cells (typically CD14+/DR-) is predictive of poor prognosis. Suppressive monocytes contribute to systemic immune suppression, prevent the differentiation of monocytes into... Read More
2010-316 – Technology Description C-type natriuretic peptide (CNP) is a 22 amino acid peptide which is primarily produced by endothelial cells and possesses potent antifibrotic and antiproliferative properties. Mayo Clinic researchers have shown that elevated levels of CNP in the urine correlate with renal fibrosis and decline in renal function. In congestive heart failure patients, urinary CNP... Read More
2009-374 – Technology Description An immunotherapy approach that delivers multiple antigens within a vesicular stomatitis virus (VSV) vector. The delivery of multiple antigens allows for a multipronged immune response against a tumor while the VSV vector serves as an activator of the innate and adaptive immune response. A three antigen combination delivered via a VSV vector has been demonstrated to be... Read More
2009-173 – Insulin-Stimulating Peptides for Diabetes and Metabolic Disorders Mayo Clinic Researchers have developed a series of peptides that have been shown to modulate glucose levels and reduce fibrotic damage to the heart and kidneys in diabetic animal models. These peptides are structural analogs of glucagon-like peptide (GLP) and natriuretic peptides. Application Control of glucose levels in... Read More
2009-172 – Glucagon-like peptide-1 (GLP-1) is derived from the transcription product of the proglucagon gene and is currently used for the management of DM. We have created a peptide with GLP-1 Properties.
2009-017 – Very long chain polyunsaturated fatty acids (VLPUFAs) are present in the human retina and play an important role in maintaining the structure and function of the retina. A disease with a defect in the gene that synthesizes VLPUFAs in the retina leads to an early onset degeneration of the macula and severe loss of vision. Currently, these VLPUFAs and other very long chain fatty acids are not... Read More
2008-332 – Both natural and chimeric natriuretic peptides have anti-proliferative properties i.e. they prevent abnormal growth, in muscle cells, endothelial cells and fibroblast cells. Blocked arteries and veins are a common cause of cardiovascular problems and blockage of muscular tubes, such as the ureter or esophagus can result serious complications. Stents are currently used to unblock blood vessel... Read More
2008-322 – Synthetic atrial natriuretic peptide (ANP) (carperitide) and B-type natriuretic peptide (BNP) (nesiritide) are used to treat congestive heart failure. However, despite beneficial cardiac unloading properties, reductions in renal perfusion pressures limit their clinical effectiveness. Recently, CD-NP, a chimeric peptide composed of CNP fused to the carboxyl terminal tail of Dendroaspis... Read More
A Novel Series of Designer Peptides Combining Angiotensin - (1-7) With Selected Amino Acid Sequences from the Natriuretic Peptides and a Novel Strategy of Co-Administration of Angiotensin - (1-7) With a Native or Designer Natriuretic Peptide
2008-179 – Our research focuses on the discovery and development of new drugs for the prevention and treatment of diseases affecting the heart, the blood vessels, and the kidneys. We have designed a novel series of ten peptides by combining angiotensin-(1-7) with selected amino sequences from the natriuretic peptides, as both angiotensin-(1-7) and the natriuretic peptides have been demonstrated to exert... Read More
2008-144 – Antibiotics fail when pathogens acquire genes that confer resistance to these drugs. This invention proposes generating vaccines specifically against the gene products of antibiotic resistance genes. These vaccines have the potential to counterselect against drug-resistant pathogens or may be used as an adjuvent to enhance drug therapy with the antibiotic by depleting the resistance gene. The... Read More
2008-001 – Adenoviruses are used for gene therapy, vaccines, and cancer killing. For gene therapy and vaccine they are generally used as non- “live” viruses and cannot make more of themselves. For cancer killing they are “live” and kill cells. This invention utilizes “single-cycle” adenoviruses for vaccine and other applications where the virus is engineered to only undergo one round of its life cycle... Read More
2007-328 – Cardiovascular disease is the leading cause of death in the United States. Our research focuses on the discovery and development of novel therapies for protecting the heart and the kidneys against harmful effects of ischemia (inadequate blood supply), heart failure, and high blood pressure. We have designed a novel peptide by combining amino acid (AA) sequences from the human natriuretic... Read More
2007-293 – Cardiovascular disease is the leading cause of death in the United States. Our research focuses on the development of novel therapies for protecting the heart and the kidneys during vulnerable periods of inadequate blood supply (ischemia) and upon restoration of blood flow (reperfusion). We designed a series of peptides by combining amino acid (AA) sequences from human natriuretic peptides... Read More
A Novel Series of Designer Natriuretic Peptides Combining the Natriuretic Peptides and Angiotensin-(1-7)
2007-196 – Heart Failure (HF) is an important public health problem and is the leading cause of hospitalization in adults over 65 years of age. Our research focuses on the development of novel therapies for the treatment of heart failure and other cardiorenal disease states. The first of this series of designer peptides is CLJB1c which consists of human C-type natriuretic peptide and angiotensin-(1-7),... Read More
2007-103 – The abnormal accumulation of TDP-43 protein has been recently identified as the major protein constituent for several neurodegenerative diseases. The protein undergoes several post-translational modifications including phosphorylation, ubiquitination and proteolytic cleavage. The pathologic accumulation of these truncated species is believed to be pathologic. Using cell culture models, we... Read More
2006-159 – The natriuretic peptide family consists of natural hormones involved in the maintenance of fluid and sodium levels through their interactions with the heart and kidneys. Mayo Clinic researchers have developed a novel natriuretic peptide (ABC) which is made up of a unique amino acid sequence designed to preferentially target the kidney to preserve its function and protect it from... Read More
2004-268 – Technology Description Mayo Clinic researchers have demonstrated that cAMP inhibitors, such as somatostatin analogs, are effective in treating polycystic liver disease in both animal models and in clinical studies. Current therapeutic options for polycystic liver disease primarily involve surgery, including liver cyst fenestration, and liver resection or liver transplantation. The... Read More
2004-085 – Tissue engineering scaffolds are biomimetic “trellis-like” structures which, on implantation and integration, act as tissue/organ surrogates. This disclosure enables the construction of multi-resolution, variably-refineable, globally interconnected, monolithic and maximally porous scaffolds.
2004-084 – Tissue engineering attempts to address the widening gap between the demand and supply of organ and tissue transplants using natural and biomimetic scaffolds. This invention provides a method to enable the repeatable and rapid fabrication of structurally and functionally enhanced and maximally characterized traditional scaffolds.
Discovery and Identification of Naturally Processed and Presented HLA Class II Measles Vaccine Virus Peptides
2004-011 – Two measles vaccine virus-derived peptides, from the nucleoprotein (N peptide) and Phosphoprotein P peptide). Specifically, 1) N-1 peptide: SAGKVSSTLASELG (14 amino acid peptide); 2) P-1 peptide: ASDVETAEGGEIHELLRLQ (19 amino acid peptide)
1998-009 – Multiple myeloma is a universally fatal plasmaproliferative disorder despite aggressive chemotherapy and transplantation. An immunotherapeutic approach to target myeloma cells for killing by toxin genes or radioisotopes may be very useful therapeutically in myeloma and such approaches have already been shown to have clinical activity in other malignancies. Our investigators have devised a... Read More